SCHEMBL23905108

SCHEMBL23905108

COc1cnc(-c2ccc(C=O)cc2)nc1OC

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.65
ALDH1A1 P00352 8/20 0.49
MEN1 O00255 3/20 0.46
NPSR1 Q6W5P4 2/20 0.46
MAPT P10636 4/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
KDM4E B2RXH2 1/20 0.42
PKM P14618 1/20 0.42
TSHR P16473 1/20 0.41
BRAF P15056 1/20 0.41
CYP2A6 P11509 1/20 0.41
GAA P10253 1/20 0.40
FPR2 P25090 1/20 0.40
FDPS P14324 1/20 0.40
POLB P06746 1/20 0.39
AOX1 Q06278 1/20 0.38
TRIM24 O15164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15577515 0.80 KMT2A (0.71) KMT2AALDH1A1MEN1NPSR1MAPT
SCHEMBL15614430 0.79 KMT2A (1.00) KMT2AALDH1A1MEN1NPSR1MAPT
SCHEMBL28312297 0.77 KMT2A (0.61) KMT2AALDH1A1MEN1NPSR1MAPT
SCHEMBL15577511 0.76 KMT2A (0.65) KMT2AALDH1A1MEN1NPSR1MAPT
SCHEMBL23905035 0.75 BRAF (0.45) ALDH1A1MAPTKDM4ETSHRBRAF
SCHEMBL23905042 0.74 ALDH1A1 (0.47) KMT2AALDH1A1MEN1MAPTTSHR
SCHEMBL15577641 0.72 KMT2A (0.60) KMT2AALDH1A1MEN1NPSR1MAPT
SCHEMBL31685827 0.72 KMT2A (0.65) KMT2AALDH1A1MEN1NPSR1MAPT
SCHEMBL23905038 0.72 ALDH1A1 (0.51) KMT2AALDH1A1MEN1NPSR1MAPT
SCHEMBL6870896 0.72 ALDH1A1 (0.43) KMT2AALDH1A1MEN1MAPTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528822-B2 Cycloalkane-1,3-diamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2026-01-20 US disclosed
US-12060365-B2 Cycloalkane-1,3-diamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2024-08-13 US disclosed
EP-3892278-B1 CYCLOALKANE-1,3-DIAMINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2024-02-28 EP disclosed
EP-3892278-B1 CYCLOALKANE-1,3-DIAMINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2024-02-28 EP disclosed
US-20230074669-A1 CYCLOALKANE-1,3-DIAMINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-03-09 US disclosed
US-20230074669-A1 CYCLOALKANE-1,3-DIAMINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-03-09 US disclosed
US-20230030720-A1 CYCLOALKANE-1,3-DIAMINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-02-02 US disclosed
US-20230030720-A1 CYCLOALKANE-1,3-DIAMINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-02-02 US disclosed
US-11236106-B2 Cycloalkane-1,3-diamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2022-02-01 US disclosed
US-11236106-B2 Cycloalkane-1,3-diamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2022-02-01 US disclosed
EP-3892278-A1 CYCLOALKANE-1,3-DIAMINE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2021-10-13 EP disclosed
EP-3892278-A1 CYCLOALKANE-1,3-DIAMINE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2021-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11236106-B2 Cycloalkane-1,3-diamine derivative MLLT1, MEN1, MLLT3 KMT2A 23/4885ALDH1A1 3327/4885MEN1 2/4885
US-12060365-B2 Cycloalkane-1,3-diamine derivative MLLT1, MEN1, MLLT3 KMT2A 23/4885ALDH1A1 3327/4885MEN1 2/4885
US-20230030720-A1 CYCLOALKANE-1,3-DIAMINE DERIVATIVE MLLT1, MEN1, MLLT3 KMT2A 23/4885ALDH1A1 3327/4885MEN1 2/4885
US-12528822-B2 Cycloalkane-1,3-diamine derivative MLLT1, MLLT3, PRMT6 KMT2A 23/4885ALDH1A1 3230/4885MEN1 15/4885
US-20230074669-A1 CYCLOALKANE-1,3-DIAMINE DERIVATIVE MLLT1, MEN1, MLLT3 KMT2A 23/4885ALDH1A1 3327/4885MEN1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.